138 related articles for article (PubMed ID: 31335393)
1. Precision Cancer Trials With Immunomodulatory Agents: Personalizing Histology Agnostic Approaches.
Baretti M; Azad NS
Cancer J; 2019; 25(4):287-295. PubMed ID: 31335393
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives.
Ciardiello D; Maiorano BA; Parente P; Rodriquenz MG; Latiano TP; Chiarazzo C; Pazienza V; Guerrera LP; Amoruso B; Normanno N; Martini G; Ciardiello F; Martinelli E; Maiello E
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055006
[TBL] [Abstract][Full Text] [Related]
3. Tumor-agnostic baskets to N-of-1 platform trials and real-world data: Transforming precision oncology clinical trial design.
Fountzilas E; Tsimberidou AM; Hiep Vo H; Kurzrock R
Cancer Treat Rev; 2024 Apr; 125():102703. PubMed ID: 38484408
[TBL] [Abstract][Full Text] [Related]
4. Biostatistical and Logistical Considerations in the Development of Basket and Umbrella Clinical Trials.
Yee LM; McShane LM; Freidlin B; Mooney MM; Korn EL
Cancer J; 2019; 25(4):254-263. PubMed ID: 31335389
[TBL] [Abstract][Full Text] [Related]
5. Future Clinical Trials: Genetically Driven Trials.
Astsaturov I
Surg Oncol Clin N Am; 2017 Oct; 26(4):791-797. PubMed ID: 28923231
[TBL] [Abstract][Full Text] [Related]
6. Precision Oncology Decision Support: Current Approaches and Strategies for the Future.
Kurnit KC; Dumbrava EEI; Litzenburger B; Khotskaya YB; Johnson AM; Yap TA; Rodon J; Zeng J; Shufean MA; Bailey AM; Sánchez NS; Holla V; Mendelsohn J; Shaw KM; Bernstam EV; Mills GB; Meric-Bernstam F
Clin Cancer Res; 2018 Jun; 24(12):2719-2731. PubMed ID: 29420224
[TBL] [Abstract][Full Text] [Related]
7. Review of precision cancer medicine: Evolution of the treatment paradigm.
Tsimberidou AM; Fountzilas E; Nikanjam M; Kurzrock R
Cancer Treat Rev; 2020 Jun; 86():102019. PubMed ID: 32251926
[TBL] [Abstract][Full Text] [Related]
8. The evolving landscape of tissue-agnostic therapies in precision oncology.
Subbiah V; Gouda MA; Ryll B; Burris HA; Kurzrock R
CA Cancer J Clin; 2024 May; ():. PubMed ID: 38814103
[TBL] [Abstract][Full Text] [Related]
9. Precision medicine clinical trials: defining new treatment strategies.
Heckman-Stoddard BM; Smith JJ
Semin Oncol Nurs; 2014 May; 30(2):109-16. PubMed ID: 24794084
[TBL] [Abstract][Full Text] [Related]
10. [Histology-agnostic tumor treatment - a farewell to tumor entities?].
Kerle I; Heining C
Dtsch Med Wochenschr; 2023 Sep; 148(18):1174-1181. PubMed ID: 37657455
[TBL] [Abstract][Full Text] [Related]
11. Translating the Science of Cancer Dormancy to the Clinic.
Aguirre-Ghiso JA
Cancer Res; 2021 Sep; 81(18):4673-4675. PubMed ID: 34429327
[TBL] [Abstract][Full Text] [Related]
12. From the Broad Phase II Trial to Precision Oncology: A Perspective on the Origins of Basket and Umbrella Clinical Trial Designs in Cancer Drug Development.
Doroshow DB; Doroshow JH
Cancer J; 2019; 25(4):245-253. PubMed ID: 31335388
[TBL] [Abstract][Full Text] [Related]
13. Agnostic drug development revisited.
Hernando-Calvo A; Rossi A; Vieito M; Voest E; Garralda E
Cancer Treat Rev; 2024 Jul; 128():102747. PubMed ID: 38763053
[TBL] [Abstract][Full Text] [Related]
14. Tumor biomarkers for diagnosis, prognosis and targeted therapy.
Zhou Y; Tao L; Qiu J; Xu J; Yang X; Zhang Y; Tian X; Guan X; Cen X; Zhao Y
Signal Transduct Target Ther; 2024 May; 9(1):132. PubMed ID: 38763973
[TBL] [Abstract][Full Text] [Related]
15. Cancer biomarkers: Emerging trends and clinical implications for personalized treatment.
Passaro A; Al Bakir M; Hamilton EG; Diehn M; André F; Roy-Chowdhuri S; Mountzios G; Wistuba II; Swanton C; Peters S
Cell; 2024 Mar; 187(7):1617-1635. PubMed ID: 38552610
[TBL] [Abstract][Full Text] [Related]
16. Tissue-agnostic drug approvals: how does this apply to patients with breast cancer?
Weis LN; Tolaney SM; Barrios CH; Barroso-Sousa R
NPJ Breast Cancer; 2021 Sep; 7(1):120. PubMed ID: 34518552
[TBL] [Abstract][Full Text] [Related]
17. Unlocking the Next Frontier in Precision Oncology: Addressing Drug-Tolerant Residual Disease.
Lin JJ; Gainor JF; Lam VK; Lovly CM
Cancer Discov; 2024 Jun; 14(6):915-919. PubMed ID: 38826097
[TBL] [Abstract][Full Text] [Related]
18. Reports from the 2010 Clinical and Translational Cancer Research Think Tank meeting: design strategies for personalized therapy trials.
Berry DA; Herbst RS; Rubin EH
Clin Cancer Res; 2012 Feb; 18(3):638-44. PubMed ID: 22298897
[TBL] [Abstract][Full Text] [Related]
19. Histology independent drug development - Is this the future for cancer drugs?
Billingham L; Brown L; Framke T; Greystoke A; Hovig E; Mathur S; Page P; Pean E; Barjesteh van Waalwijk van Doorn-Khosrovani S; Vonk R; Wissink S; Zander H; Plummer R
Cancer Treat Rev; 2024 Feb; 123():102674. PubMed ID: 38176220
[TBL] [Abstract][Full Text] [Related]
20. Framework for the Use of External Controls to Evaluate Treatment Outcomes in Precision Oncology Trials.
Siu DHW; Lin FPY; Cho D; Lord SJ; Heller GZ; Simes RJ; Lee CK
JCO Precis Oncol; 2024 Jan; 8():e2300317. PubMed ID: 38190581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
